



The oncology field continues to evolve rapidly in areas of cancer biology and in harnessing immune biology for next generation therapies. We are prioritizing our emerging pipeline efforts in the pursuit of curative therapies, with a focus on novel mechanisms in the cancer-immunity cycle.



HEMATOLOGIC MALIGNANCIES



SOLID TUMORS

MARKETED AND LATE STAGE

HEMATOLOGIC MALIGNANCIES

BRENTUXIMAB VEDOTIN¹
CD30 Monoclonal Antibody Drug Conjugate
Peripheral T-Cell Lymphoma



IXAZOMIB
Proteasome Inhibitor
Multiple Myeloma



PONATINIB²
BCR-ABL Inhibitor
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia



PEVONEDISTAT
NEDD8-Activating Enzyme Inhibitor
Higher-Risk Myelodysplastic Syndromes, Higher-Risk Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia



BRIGATINIB
Anaplastic Lymphoma Kinase Inhibitor
ALK+ Non-Small Cell Lung Cancer



CABOZANTINIB³
VEGFR/RTK Inhibitor
Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Prostate Cancer



NIRAPARIB⁴
PARP 1/2 Inhibitor
Ovarian Cancer, Prostate Cancer



RELUGOLIX⁵
GnRH Antagonist
Prostate Cancer



MOBOCERTINIB
EGFR/HER2 Inhibitor
Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation



PIPELINE

NEXT-GEN INNATE AND CHECKPOINT MODULATORS

TAK-981
SUMO Activating Enzyme Inhibitor
Solid Tumors, Hematologic Malignancies



TAK-676
STING Agonist
Solid Tumors



TAK-605⁹
Oncolytic Virus
Solid Tumors



TAK-252⁸
Agonist Redirected Checkpoint Fusion Protein PD1/OX40L
Solid Tumors, Lymphomas



TAK-169
CD38 Targeted Engineered Toxin Body
Multiple Myeloma



TAK-186¹⁰
Conditional EGFR-targeting T-cell Engager
Solid Tumors



TAK-573
CD38 Attenukine
Solid Tumors, Multiple Myeloma



CELL THERAPY

TAK-007⁶
CD19 CAR-NK
Relapsed/Refractory B-Cell Malignancies



TAK-940¹¹
CD19 1XX CAR-T
Relapsed/Refractory B-Cell Malignancies



TAK-102⁷
GPC3 CAR-T
Solid Tumors



All programs have Global Development Rights unless otherwise noted.

¹ Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. ² Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). ³ Japan Only. In partnership with Exelixis, Inc. ⁴ Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. ⁵ Japan and Asian countries. In partnership with Myovant Sciences, Inc. ⁶ Under licensing agreement and in collaboration with MD Anderson Cancer Center. ⁷ Collaboration with Noile-Immune Biotech. ⁸ Takeda retains an option to develop TAK-252 / SL-279252 with Shattuck Labs. ⁹ In Collaboration with Turnstone Biologics. ¹⁰ Takeda shares development rights for TAK-186 with Maverick Pharma Pvt. Ltd. ¹¹ In Collaboration with Memorial Sloan Kettering Cancer Center.

VV-MEDMAT-29054 11/2020

Reference: <https://www.clinicaltrials.gov> (last accessed November, 2020)

ALL PRODUCTS LISTED ARE INVESTIGATIONAL IN THE SETTING IN WHICH THEY ARE CURRENTLY BEING STUDIED AND NOT APPROVED FOR THESE INDICATIONS, SAFETY AND EFFICACY NOT YET ESTABLISHED (SEE CLINICALTRIALS.GOV).